210 related articles for article (PubMed ID: 34289901)
21. Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy.
Bachvarov D; L'esperance S; Popa I; Bachvarova M; Plante M; Têtu B
Int J Oncol; 2006 Oct; 29(4):919-33. PubMed ID: 16964388
[TBL] [Abstract][Full Text] [Related]
22. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
23. Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma.
Yano M; Miyazawa M; Ogane N; Ogasawara A; Hasegawa K; Narahara H; Yasuda M
Anticancer Res; 2021 Mar; 41(3):1647-1654. PubMed ID: 33788761
[TBL] [Abstract][Full Text] [Related]
24. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
Meisel JL; Hyman DM; Garg K; Zhou Q; Dao F; Bisogna M; Gao J; Schultz ND; Grisham RN; Phillips M; Iasonos A; Kauff ND; Levine DA; Soslow RA; Spriggs DR
Ann Oncol; 2014 Dec; 25(12):2372-2378. PubMed ID: 25281711
[TBL] [Abstract][Full Text] [Related]
25. Hypomethylation signature of tumor-initiating cells predicts poor prognosis of ovarian cancer patients.
Liao YP; Chen LY; Huang RL; Su PH; Chan MW; Chang CC; Yu MH; Wang PH; Yen MS; Nephew KP; Lai HC
Hum Mol Genet; 2014 Apr; 23(7):1894-906. PubMed ID: 24256813
[TBL] [Abstract][Full Text] [Related]
26. Hypermethylation of tumor suppressor genes is a risk factor for poor prognosis in ovarian cancer: A meta-analysis.
Feng LY; Chen CX; Li L
Medicine (Baltimore); 2019 Feb; 98(8):e14588. PubMed ID: 30813180
[TBL] [Abstract][Full Text] [Related]
27. HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance.
Iramaneerat K; Rattanatunyong P; Khemapech N; Triratanachat S; Mutirangura A
Int J Gynecol Cancer; 2011 Jan; 21(1):51-7. PubMed ID: 21330831
[TBL] [Abstract][Full Text] [Related]
28. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
29. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers.
Gull N; Jones MR; Peng PC; Coetzee SG; Silva TC; Plummer JT; Reyes ALP; Davis BD; Chen SS; Lawrenson K; Lester J; Walsh C; Rimel BJ; Li AJ; Cass I; Berg Y; Govindavari JB; Rutgers JKL; Berman BP; Karlan BY; Gayther SA
J Exp Clin Cancer Res; 2022 Jul; 41(1):232. PubMed ID: 35883104
[TBL] [Abstract][Full Text] [Related]
31. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles.
Bauerschlag DO; Ammerpohl O; Bräutigam K; Schem C; Lin Q; Weigel MT; Hilpert F; Arnold N; Maass N; Meinhold-Heerlein I; Wagner W
Oncology; 2011; 80(1-2):12-20. PubMed ID: 21577013
[TBL] [Abstract][Full Text] [Related]
32. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract][Full Text] [Related]
33. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
[TBL] [Abstract][Full Text] [Related]
34. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
Schmid G; Notaro S; Reimer D; Abdel-Azim S; Duggan-Peer M; Holly J; Fiegl H; Rössler J; Wiedemair A; Concin N; Altevogt P; Marth C; Zeimet AG
BMC Cancer; 2016 Feb; 16():102. PubMed ID: 26879132
[TBL] [Abstract][Full Text] [Related]
35. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
[TBL] [Abstract][Full Text] [Related]
36. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
Meng Q; Duan P; Li L; Miao Y
Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
[TBL] [Abstract][Full Text] [Related]
37. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
38. ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.
Mase S; Shinjo K; Totani H; Katsushima K; Arakawa A; Takahashi S; Lai HC; Lin RI; Chan MWY; Sugiura-Ogasawara M; Kondo Y
Cancer Sci; 2019 Mar; 110(3):1105-1116. PubMed ID: 30633424
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Bernards SS; Pennington KP; Harrell MI; Agnew KJ; Garcia RL; Norquist BM; Swisher EM
Gynecol Oncol; 2018 Feb; 148(2):281-285. PubMed ID: 29233532
[TBL] [Abstract][Full Text] [Related]
40. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.
Keita M; Wang ZQ; Pelletier JF; Bachvarova M; Plante M; Gregoire J; Renaud MC; Mes-Masson AM; Paquet ÉR; Bachvarov D
Gynecol Oncol; 2013 Feb; 128(2):356-63. PubMed ID: 23219462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
